Which ASX shares could be next on the menu for Ozempic?

This broker believes the market for weight-loss drugs could grow tenfold. What could it consume on its way up?

A person eats a meat pie on the beach... what's more Australian than that?

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Analysts at Morgan Stanley think investors won't have the stomach for certain shares if Ozempic and others like it continue to rise in popularity.

The use of weight-loss drugs is showing no signs of slowing down. Glucagon-like peptide-1 (GLP-1) maker Novo Nordisk (NYSE: NVO) jacked up its full-year profit and sales estimates last week on an insatiable appetite for its slimming medication.

While Morgan Stanley is seeing growth in the weight-loss medication market, other industries have been spotlighted as possible dietary do-aways.

Ozempic threatens high-calorie ASX shares

Newton's Third Law: For every action, there is an equal and opposite reaction. If weight-loss drugs reduce appetite, there must be an 'equal and opposite reaction'. Well, it turns out the team at Morgan Stanley thinks so.

A report compiled by the analysts forecasts a base scenario of a US$105 billion category by 2030. The more optimistic 'bull case' estimates that weight-loss drugs could be a market worth more than US$140 billion in six years.

But where's the other part of Newton's equation?

It turns out the implications could be right on our doorstep. Australia is a hotbed for GLP-1s, according to the broker. The country's high obesity rate places it in pole position for highest demand across the Asia Pacific locale.

Food consumption is the most obvious reaction to increased Ozempic uptake. Morgan Stanley names Woolworths Group Ltd (ASX: WOW) and Coles Group Ltd (ASX: COL) as shares that could face the Ozempic chomp.

The broker also picks out certain food groups susceptible to calorie suppression, writing:

Our analysis suggests ice cream, cakes, cookies, candy, chocolate, frozen pizzas, chips, and regular sodas could see 4% to 5% reductions in consumption by 2035.

Alcohol faces the most pronounced risk in the beverages category with some GLP-1 patients citing a foregoing of alcohol consumption entirely

Quick service restaurants with a focus on unhealthy food items, including fried chicken and pizza, present with greater risks from a consumption standpoint, and could require menu adaptation.

It's not hard to imagine which listed companies deal in the abovementioned areas. This might suggest that Ozempic threatens ASX shares such as Domino's Pizza Enterprises Ltd (ASX: DMP), Endeavour Group Ltd (ASX: EDV), and KFC operator Collins Foods Ltd (ASX: CKF).

Does Resmed make the list?

Despite being the poster child for Ozempic disruption early on, Resmed CDI (ASX: RMD) was not one Morgan Stanley warned of in its report. Neither was it labelled as a beneficiary.

Instead, the broker presented a more balanced outlook for the sleep apnea device maker, stating:

It is conceivable that GLP-1s drive increased awareness and interaction with the healthcare system among patients with obesity, leading to higher rates of diagnosis for obstructive sleep apnoea and ultimately some increased penetration to partially offset the patient losses.

The Resmed share price suffered an unceremonious dumping last year. Fear gripped the ASX healthcare share after a link between obesity and sleep apnea was made. The Ozempic concern sent shares down 36% before it began to recover.

Motley Fool contributor Mitchell Lawler has positions in ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Domino's Pizza Enterprises and ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Novo Nordisk. The Motley Fool Australia has positions in and has recommended Coles Group and ResMed. The Motley Fool Australia has recommended Collins Foods and Domino's Pizza Enterprises. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Consumer Staples & Discretionary Shares

Cheerful Father And Son Competing In Video Games At Home
Share Market News

Here's how the ASX 200 market sectors stacked up last week

ASX consumer discretionary shares rose by more than 3% last week.

Read more »

A mature aged man with grey hair and glasses holds a fan of Australian hundred dollar bills up against his mouth and looks skywards with his eyes as though he is thinking what he might do with the cash.
Consumer Staples & Discretionary Shares

Is now the time to buy this high-yielding ASX dividend stock?

This stock could be ripe for an investment.

Read more »

A couple in a supermarket laugh as they discuss which fruits and vegetables to buy
Broker Notes

Why Goldman Sachs just upgraded Coles shares

The broker has become a lot more positive on this supermarket giant.

Read more »

A customer and shopper at the checkout of a supermarket.
Consumer Staples & Discretionary Shares

Why this could be the best ASX 200 consumer staples stock to buy in May

Here's why I think this stock is a great buying opportunity in May.

Read more »

A woman has a big smile on her face as she drives her 4WD along the beach.
Share Gainers

Why this $1.5 billion ASX 200 stock just surged 10%

ASX 200 investors are sending the stock surging on Tuesday. But why?

Read more »

A group of young ASX investors sitting around a laptop with an older lady standing behind them explaining how investing works.
Consumer Staples & Discretionary Shares

Top fundie says this heavily shorted ASX 200 stock is 'cheaper than it's worth'

Learn here about an ASX 200 stock this Airlie fund manager likes.

Read more »

A laughing woman pushes her friend, who has her arms outstretched, in a supermarket trolley.
Broker Notes

Coles share price holds firm while Woolworths tumbles 18% in 2024. Time to buy?

We canvas the views of a few top brokers on whether Coles shares are a good buy today.

Read more »

Coles Woolworths supermarket warA man and a woman line up to race through a supermaket, indicating rivalry between the mangorsupermarket shares

Which of these ASX 200 shares is the better bargain in May?

Here's my take on Coles vs. Woolies...

Read more »